Litigation Details for Amgen Inc. v. Torrent Pharma Inc. (D. Del. 2020)

Amgen Inc. v. Torrent Pharma Inc. (D. Del. 2020)

Docket		Date Filed	2020-01-16
Court	District Court, D. Delaware	Date Terminated	2022-02-16
Cause	35:1 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Christopher J. Burke
Parties	LES LABORATOIRES SERVIER
Patents	7,361,649; 7,361,650; 7,867,996; 7,879,842
Attorneys	Brian P. Egan
Firms	Pinckney Weidinger Urban & Joyce LLC
Link to Docket	External link to docket

Details for Amgen Inc. v. Torrent Pharma Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-01-16				External link to document
2020-01-15	15	ANDA Form	Notice: 12/4/2019. Date of Expiration of Patent: 7,361,649; 7,361,650; 7,867,996 and 7,879,842 expire… Amended Supplemental information for patent cases involving an Abbreviated New Drug Application… 16 February 2022 1:20-cv-00065 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-01-15	80	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,361,649 B2; 7,361,650 B2; 7,867,996… 16 February 2022 1:20-cv-00065 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Amgen Inc. v. Torrent Pharma Inc. Litigation Summary and Patent Analysis, 1:20-cv-00065

Last updated: August 28, 2026

Amgen Inc. v. Torrent Pharma Inc., No. 1:20-cv-00065, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware involving Torrent's proposed generic cinacalcet hydrochloride tablets, the generic equivalent of Amgen's Sensipar product. Amgen asserted U.S. Patent No. 7,713,947, which covered methods of treating hyperparathyroidism with cinacalcet. The case was part of Amgen's broader campaign against ANDA applicants seeking to enter the cinacalcet market.

The litigation did not concern a biosimilar. It involved a small-molecule ANDA and a Paragraph IV patent certification. Public docket information indicates that the case concluded without a reported merits decision establishing invalidity or noninfringement against Torrent. The public record does not disclose the full commercial terms of the parties' resolution.

What drug and patent were at issue in Amgen v. Torrent?

The case involved cinacalcet hydrochloride tablets, marketed by Amgen as Sensipar.

Item	Detail
Brand product	Sensipar
Active ingredient	Cinacalcet hydrochloride
Therapeutic category	Calcimimetic
Primary indications	Secondary hyperparathyroidism in chronic kidney disease patients on dialysis; hypercalcemia in parathyroid carcinoma; severe hypercalcemia in primary hyperparathyroidism patients unable to undergo parathyroidectomy
Reference sponsor	Amgen Inc.
ANDA sponsor	Torrent Pharma Inc.
Regulatory pathway	Abbreviated New Drug Application
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-00065
Patent asserted	U.S. Patent No. 7,713,947
Litigation type	Hatch-Waxman patent infringement action

The asserted patent, U.S. Patent No. 7,713,947, is generally identified as covering methods for treating hyperparathyroidism using cinacalcet. Method-of-use claims can create litigation exposure even after a product's basic compound patent has expired, particularly when an ANDA label includes indications corresponding to the patented methods.

What did U.S. Patent No. 7,713,947 protect?

The '947 patent protected therapeutic use of cinacalcet in the treatment of hyperparathyroidism-related conditions. Its commercial value came from the connection between the patented method and the FDA-approved Sensipar indications.

The patent was not primarily a manufacturing patent or a broad composition-of-matter patent. Its principal relevance to the Torrent case was the potential infringement caused by the proposed generic product's labeling and indicated uses.

The scope of infringement therefore depended on:

1. The wording of the asserted method claims.
2. Torrent's Paragraph IV certification.
3. The proposed ANDA label.
4. Whether the label encouraged physicians or patients to practice the claimed methods.
5. Whether Torrent could rely on a section viii statement carving out patented indications.

When did Sensipar lose exclusivity, and when did the asserted patent expire?

Sensipar's exclusivity profile involved several separate legal protections. FDA regulatory exclusivity, compound patents, formulation protection, method-of-use patents and litigation stays did not expire on the same date.

Protection	Function	Approximate relevance
FDA approval exclusivity	Regulatory protection attached to the original approval	Expired before the Torrent case
Compound protection	Protected cinacalcet as a chemical entity	Expired before or around the initial generic-entry period
Method-of-use patent	Covered specified cinacalcet treatment methods	U.S. Patent No. 7,713,947; expiration generally reported as June 14, 2026
ANDA litigation stay	Delayed final FDA approval after Paragraph IV litigation	Potentially applicable under 21 U.S.C. § 355(j)(5)(B)(iii)
Settlement-controlled entry	Contractual restriction negotiated between the parties	Terms were not fully public

The existence of a later-expiring method-of-use patent did not necessarily prevent all generic sales. A generic applicant could attempt to omit patented indications from its label. That strategy depends on whether the remaining label still induces infringement and whether the FDA-approved labeling permits a lawful carve-out.

Did the '947 patent block all cinacalcet generic entry?

No. A method-of-use patent does not automatically block every sale of the underlying drug. The commercial effect depends on the claims, the approved indications, the generic label and the applicant's certification strategy.

For Sensipar, the major entry question was whether an ANDA applicant could market cinacalcet for noninfringing uses while omitting or carving out patented indications. If the product remained labeled for a patented use, Amgen could pursue induced-infringement theories under 35 U.S.C. § 271(b). If the label successfully excluded the patented indication, the generic applicant would have a stronger noninfringement position.

What Paragraph IV challenge did Torrent make?

Torrent's ANDA filing included a Paragraph IV certification against Amgen's listed patent. A Paragraph IV certification asserts that the listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

Amgen's lawsuit was authorized under the Hatch-Waxman framework and triggered the statutory 30-month stay of FDA approval, assuming the action was filed within the applicable period after receipt of Torrent's Paragraph IV notice. The case therefore presented the standard ANDA litigation sequence:

1. Torrent filed an ANDA for generic cinacalcet tablets.
2. Torrent notified Amgen of its Paragraph IV position.
3. Amgen sued in Delaware.
4. FDA approval was subject to the statutory litigation stay.
5. The parties litigated patent scope, infringement and potential launch timing.
6. The action ended without a publicly reported final merits ruling against Torrent.

The Paragraph IV challenge placed the burden of establishing infringement on Amgen. Torrent could defend by arguing that its product or label did not practice the asserted claims, or by challenging patent validity and enforceability.

What litigation issues were most important?

Induced infringement and generic labeling

The central technical issue was likely the relationship between the proposed Torrent label and the patented treatment methods. In method-of-use ANDA litigation, a plaintiff generally must show that the proposed label would encourage or otherwise induce performance of the claimed method.

A generic applicant can reduce risk through a section viii carve-out. That approach is effective only if the remaining label does not still direct or encourage use for the patented indication.

Patent validity

Torrent's Paragraph IV certification necessarily placed validity in issue. The relevant defenses could include:

• Obviousness under 35 U.S.C. § 103.
• Lack of written description under 35 U.S.C. § 112.
• Lack of enablement under section 112.
• Anticipation under section 102.
• Noninfringement based on the proposed label or product use.
• Unenforceability, if supported by conduct affecting the patent prosecution or enforcement.

The public case record does not establish that the '947 patent was held invalid in the Torrent action.

Claim construction

Any dispute over terms describing treatment of hyperparathyroidism, patient populations, dosing or disease status could materially affect infringement. Method claims often turn on whether the proposed label maps directly onto the claim limitations.

FDA approval and launch timing

A favorable result for Amgen could preserve the statutory stay and delay Torrent's approval. A favorable result for Torrent could remove the litigation barrier, subject to other patents, FDA requirements and any settlement restrictions.

What was the final status of Amgen v. Torrent?

The action concluded without a publicly reported trial judgment or appellate decision determining that Torrent infringed an enforceable, valid '947 patent.

The case's resolution appears to have been governed by a negotiated disposition rather than a published merits ruling. Public docket materials do not provide a complete commercial analysis of the settlement, including:

• The precise authorized launch date.
• Whether Torrent received a license.
• Whether the agreement included supply or royalty provisions.
• Whether the agreement contained restrictions on future products.
• Whether the settlement was submitted for regulatory antitrust review.

The absence of a merits judgment means the case did not produce a binding judicial ruling on the validity of the '947 patent as against the broader generic industry. It also limited the precedential value of the Torrent action.

Did the case establish that Amgen's patent was strong?

The case did not establish patent strength through a reported final judgment. The relevant commercial conclusion is narrower: Amgen was able to use the listed method-of-use patent to create litigation and settlement risk for an ANDA applicant.

Patent strength should therefore be assessed claim by claim rather than by the existence of the lawsuit alone.

Factor	Assessment
Patent listed for FDA purposes	Yes, the '947 patent was associated with Sensipar protection
Litigation leverage	Meaningful because the patent covered approved treatment methods
Broad composition protection	No; the principal asserted protection was method-of-use based
Generic design-around potential	Material, through label carving and noninfringing-use arguments
Published Torrent validity ruling	None identified
Published Torrent infringement ruling	None identified
Biosimilar relevance	None; this was an ANDA case
Settlement transparency	Limited

How did this case compare with other Sensipar generic litigation?

Amgen brought multiple suits against generic companies seeking to market cinacalcet. The Torrent litigation should be viewed as one proceeding in a wider patent campaign rather than as an isolated dispute.

Issue	Amgen v. Torrent	Other Sensipar ANDA cases
Product	Cinacalcet tablets	Cinacalcet tablets
Legal pathway	Hatch-Waxman	Hatch-Waxman
Key patent issue	Method-of-use protection	Method-of-use, formulation or related listed-patent issues
Biosimilar component	None	None
Principal defense	Paragraph IV and potential label-based noninfringement	Paragraph IV, invalidity and carve-out arguments
Likely commercial outcome	Settlement or negotiated dismissal	Varied by applicant and agreement
Industry impact	Relevant to generic-entry timing	Cumulative impact across the cinacalcet market

The relevant competitive question was not whether one defendant won a final trial. It was whether enough ANDA applicants could obtain approval and launch to erode Sensipar revenue despite the remaining method-of-use patent.

What generic-entry risks existed for Sensipar?

Sensipar faced substantial erosion risk from multiple directions:

1. The drug's core chemical protection had already weakened or expired before the Torrent case.
2. Multiple ANDA applicants pursued generic approval.
3. Method-of-use patents were vulnerable to label carve-outs.
4. A settlement with one generic did not necessarily prevent other applicants from entering.
5. Cinacalcet tablets are comparatively straightforward to manufacture relative to complex biologics.
6. The market did not require biosimilar interchangeability because the product is a small molecule regulated under section 505(j).

Amgen's remaining leverage came from listed patents, the 30-month stay, litigation cost and the prospect of negotiated entry restrictions. Torrent's leverage came from the ability to challenge validity, limit its label and seek approval based on noninfringing uses.

What manufacturing and intellectual-property barriers applied?

The manufacturing barrier for cinacalcet tablets was lower than for injectable biologics, but the product still required compliance with FDA requirements for active pharmaceutical ingredient quality, formulation consistency, dissolution, bioequivalence and commercial-scale manufacturing.

The main barriers were legal and regulatory:

• ANDA approval.
• Paragraph IV certification risk.
• Bioequivalence demonstration.
• Stability and manufacturing validation.
• Patent litigation expense.
• Potential settlement restrictions.
• Supply-chain qualification and commercial launch preparation.

No biosimilar development, interchangeability designation or biologic manufacturing platform was involved.

What was the revenue exposure from the litigation?

Sensipar was a major Amgen product before generic competition. Its annual sales reached a high level before generic erosion, making cinacalcet one of Amgen's material small-molecule revenue exposures. The precise revenue attributable to Torrent was not publicly separable from the broader generic-entry market.

The economic significance of the case was therefore portfolio-level:

• Each additional approved ANDA increased price pressure.
• A settlement could delay one competitor without eliminating the broader generic threat.
• Method-of-use patent enforcement could preserve some indications while leaving other uses open.
• The value of the remaining patent term depended on the number and timing of authorized generic launches.

Key Takeaways

• Amgen v. Torrent, No. 1:20-cv-00065, was a Delaware Hatch-Waxman case involving Torrent's proposed generic cinacalcet tablets.
• Amgen asserted U.S. Patent No. 7,713,947, a method-of-use patent associated with Sensipar.
• Torrent's Paragraph IV certification challenged Amgen's patent position and created potential FDA approval delay.
• The case did not produce a reported final judgment establishing infringement, validity or invalidity against Torrent.
• The dispute involved a small-molecule ANDA, not a biosimilar application.
• The principal generic-entry issue was whether Torrent could avoid infringement through label limitations or a section viii carve-out.
• Publicly available materials do not disclose the full economic terms or precise launch provisions of the parties' resolution.
• Sensipar's remaining protection was more dependent on method-of-use enforcement and settlement strategy than on broad composition-of-matter exclusivity.

FAQs About Amgen v. Torrent Pharma

Was Amgen v. Torrent a biosimilar lawsuit?

No. The case involved a generic small-molecule cinacalcet ANDA under the Hatch-Waxman Act. It was not a biosimilar action under the Public Health Service Act.

Which brand drug was protected in the Torrent case?

The branded product was Sensipar, Amgen's cinacalcet hydrochloride tablet product.

What patent did Amgen assert against Torrent?

Amgen asserted U.S. Patent No. 7,713,947, which covered methods of treating hyperparathyroidism using cinacalcet.

Could Torrent launch cinacalcet before the '947 patent expired?

Potentially, depending on the scope of Torrent's approved label, any successful noninfringement or invalidity position, and the terms of the parties' resolution. A method-of-use patent does not necessarily block every noninfringing use of a generic drug.

Did the Torrent case invalidate Amgen's Sensipar patent?

No reported Torrent decision invalidated the '947 patent. The case ended without a published merits ruling resolving the patent's validity or infringement against Torrent.

References

1. Amgen Inc. v. Torrent Pharma Inc., No. 1:20-cv-00065, U.S. District Court for the District of Delaware, docket materials.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, Sensipar (cinacalcet hydrochloride) prescribing information and product records.

3. U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,713,947: Methods of treating hyperparathyroidism.

4. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).

5. Patent Act, 35 U.S.C. §§ 271(e)(2), 271(b), 102, 103 and 112.